-
Product Insights
NewChoroidal Neovascularization – Drugs In Development, 2024
Empower your strategies with our Choroidal Neovascularization – Drugs In Development, 2024 report and make more profitable business decisions. Choroidal neovascularization (CNV) involves the growth of new blood vessels that originate from the choroid, the pigmented vascular layer of tissue behind the retina. Symptoms include painless loss of vision, metamorphopsia, and color disturbances. Treatment includes anti-vascular endothelial growth factor (anti-VEGF) agents, laser photocoagulation, and photodynamic therapy. The Choroidal Neovascularization drugs in development market research report provide comprehensive information on the therapeutics...
-
Product Insights
NewPost Menopausal Osteoporosis – Drugs In Development, 2024
Empower your strategies with our Post Menopausal Osteoporosis – Drugs In Development, 2024 report and make more profitable business decisions. Postmenopausal osteoporosis is the most common form of osteoporosis. It affects many women after menopause. Symptoms include back pain, loss of height, or spinal deformities such as stooped posture. Risk factors include age, gender, family history, bone structure, and body weight. Treatment includes hormone replacement therapy (HRT) and vitamin D analogues. The Post Menopausal Osteoporosis drugs in development market research report...
-
Product Insights
NewPlaque Psoriasis (Psoriasis Vulgaris) – Drugs In Development, 2024
Empower your strategies with our Plaque Psoriasis (Psoriasis Vulgaris) – Drugs In Development, 2024 report and make more profitable business decisions. Plaque psoriasis, also known as psoriasis vulgaris, is the most common form of psoriasis, a chronic skin condition characterized by the rapid buildup of skin cells. It results from an overactive immune system, causing skin cells to accumulate on the surface, forming thick, scaly, and often itchy patches or plaques. These patches can vary in size and typically have a...
-
Product Insights
NewOsteoporosis – Drugs In Development, 2024
Empower your strategies with our Osteoporosis – Drugs In Development, 2024 report and make more profitable business decisions. Osteoporosis, or thinning bones, makes bones weak and more likely to break. Risk factors for osteoporosis include aging, being female, low body weight, low sex hormones or menopause, smoking, and some medications. Signs and symptoms include back pain, caused by a fractured or collapsed vertebra, loss of height over time, a stooped posture, and a bone fracture that occurs much more easily than...
-
Product Insights
Injectable Drug Delivery Pipeline by Development Stages, Segments, Region and Countries, Regulatory Path and Key Companies
Injectable Drug Delivery Pipeline Market Report Overview Injectable drug delivery devices help administer a drug into a patient’s blood. The Injectable Drug Delivery pipeline market research report provides a comprehensive understanding of the pipeline products along with their comparative analysis at various stages of development. The report also includes information about the territories wherein the clinical trials are in progress, the regulatory paths followed by the trials, and the companies associated with the trials. Key Segments · Sustained Release Injectable...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Pegenzileukin in Colon Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Pegenzileukin in Colon Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pegenzileukin in Colon Cancer Drug Details: SAR-444245 (THOR-707) is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Golimumab Biosimilar in Inflammation
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Golimumab Biosimilar in Inflammation report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Golimumab Biosimilar in Inflammation Drug Details:Monoclonal antibody is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – (Febuxostat + Inosine) in Mitochondrial Diseases
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - (Febuxostat + Inosine) in Mitochondrial Diseases report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.(Febuxostat + Inosine) in Mitochondrial DiseasesDrug Details:A fixed dose combination of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Golimumab Biosimilar in Rheumatoid Arthritis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Golimumab Biosimilar in Rheumatoid Arthritis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Golimumab Biosimilar in Rheumatoid ArthritisDrug Details:Monoclonal antibody is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Aflibercept Biosimilar in Wet (Neovascular / Exudative) Macular Degeneration
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Aflibercept Biosimilar in Wet (Neovascular / Exudative) Macular Degeneration report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Aflibercept Biosimilar in Wet (Neovascular /...